Arsenic exposure and bladder cancer: Quantitative assessment of studies in human populations to detect risks at low doses

Toxicology

Volumn 317, Issue 1, 2014, Pages 17-30

  Tsuji, Joyce S ^a   Alexander, Dominik D ^a   Perez, Vanessa ^a   Mink, Pamela J ^b  

^a EXPONENT INC   (United States)

^b Allina Medical Systems   (United States)

Author keywords

Arsenic; Bladder cancer risk; Drinking water; Meta analysis; Risk assessment

Indexed keywords

ARSENIC;

ARTICLE; BLADDER CANCER; DOSE RESPONSE; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ARSENIC; BLADDER CANCER RISK; DRINKING WATER; META-ANALYSIS; RISK ASSESSMENT;

ANIMALS; ARSENIC; CARCINOGENS, ENVIRONMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; EVIDENCE-BASED PRACTICE; HUMANS; RISK ASSESSMENT; SMOKING; UNCERTAINTY; URINARY BLADDER NEOPLASMS; WATER POLLUTANTS, CHEMICAL; WATER QUALITY; WORLD HEALTH;

EID: 84893607507     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.01.004     Document Type: Article

References (76)

1. Cancer Facts & Figures 2013, American Cancer Society (ACS), American Cancer Society, Atlanta, GA.
2. Arnold L.L., Suzuki S., Yokohira M., Kakiuchi-Kiyota S., Pennington K.L., Cohen S.M. Time course of urothelial changes in rats and mice orally administered arsenite. Toxicol. Pathol. 2013, PMID: 23690446.
3. Baastrup R., Sørensen M., Balstrøm T., Frederiksen K., Larsen C.L., Tjønneland A., Overvad K., Raaschou-Nielsen O. Arsenic in drinking-water and risk for cancer in Denmark. Environ. Health Perspect. 2008, 116(2):231-237.
4. Bates M.N., Smith A.H., Cantor K.P. Case-control study of bladder cancer and arsenic in drinking water. Am. J. Epidemiol. 1995, 141(6):523-530.
5. Bates M.N., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Kalman D., Steinmaus C., Smith A.H. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol. 2004, 159(4):381-389.
6. Beebe-Dimmer J.L., Iyer P.T., Nriagu J.O., Keele G.R., Mehta S., Meliker J.R., Lange E.M., Schwartz A.G., Zuhlke K.A., Schottenfeld D., Cooney K.A. Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. Environmental Health: a global access science source. Environ. Health 2012, 11:43. 10.1186/1476-069X-11-43.
7. Begum M., Horowitz J., Hossain M.I. Low-dose risk assessment for arsenic: a meta-analysis approach. Asia-Pacific J. Public Health 2012, 10.1177/1010539512466568.
8. Brenner H., Savitz D., Jockel K.-H., Greenland S. Effects of nondifferential exposure misclassification in ecologic studies. Am. J. Epidemiol. 1992, 135:85-95.
9. Brown K.G. How creditable are cancer risk estimates from the S.W. Taiwan database for arsenic in drinking water?. Hum. Ecol. Risk Assess. 2007, 13:190.
10. Cantor K.P., Lubin J.H. Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations. Toxicol. Appl. Pharmacol. 2007, 222(3):252-257.
11. Castelao J.E., Yuan J.-M., Skipper P.L., Tannenbaum S.R., Gag-Dominguez M., Crowder J.S., Ross R.K., Yu M.C. Gender- and smoking-related bladder cancer risk. J. Natl. Cancer Inst. 2001, 93:538-545.
12. Chen C.-J., Chuang Y.-C., You S.-L., Lin T.-M., Wu H.-Y. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br. J. Cancer 1986, 53:399-405.
13. Chen C.-J., Wu M.-M., Lee S.-S., Wang J.-D., Cheng S.-H., Wu H.-Y. Atherogenicity and carcinogencity of high-arsenic artesian well water multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988, 8:452-460.
14. Chen C.J., Chen C.W., Wu M.M., Kuo T.L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 1992, 66(5):888-892.
15. Chen C.-J., Hsueh Y.-M., Tseng M.-P., Lin Y.-C., Hsu L.-I., Chou W.-L., Chiou H.-Y., Wang I.-H., Chou Y.-L., Tseng C.-H., Liou S.-H. Individual susceptibility to arseniasis. Proceedings of the Fourth Annual International Conference on Arsenic Exposure and Health Effects, 18-22 June 2000 2001, 135-143. Elsevier Science Ltd. W.R. Chappell, C.O. Abernathy, R.L. Calderon (Eds.).
16. Chen C.-L., Chiou H.-Y., Hsu L.-I., Hsueh Y.-M., Wu M.-M., Wang Y.-H., Chen C.-J. Arsenic in drinking water and risk of urinary tract cancer: a follow-up study from northeastern Taiwan. Cancer Epidemiol. Biomark. Prev. 2010, 19(1):101-110.
17. Chen C.-L., Chiou H.-Y., Hsu L.-I., Hsueh Y.-M., Wu M.-M., Chen C.-J. Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. Environ. Res. 2010, 110(5):455-462.
18. Chen Y., Graziano J.H., Parvez F., Liu M., Slavkovich V., Kalra T., Argos M., Islam T., Ahmed A., Rakibuz-Zaman M., Hasan R., Sarwar G., Levy D., van Geen A., Ahsan H. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. Br. Med. J. 2011, 342:d2431.
19. Chiou H.-Y., Chiou S.-T., Hsu Y.-H., Chou Y.-L., Tseng C.-H., Wei M.-L., Chen C.-J. incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am. J. Epidemiol. 2001, 153(5):411-418.
20. Clewell H.J., Thomas R.S., Kenyon E.M., Hughes M.F., Adair B.M., Gentry P.R., Yager J.W. Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeks. Toxicol. Sci. 2011, 123(2):421-432.
21. Cohen S.M., Arnold L.L. Chemical carcinogenesis. Toxicol. Sci. 2011, 120(S1):S76-S92.
22. Cohen S.M., Arnold L.L., Beck B.D., Lewis A.S., Eldan M. Evaluation of the carcinogenicity of inorganic arsenic. Crit. Rev. Toxicol. 2013, 43(9):711-752.
23. Crump K.S. The effect of random error in exposure measurement upon the shape of the exposure response. Dose-Response 2005, 3:456-464.
24. Dallongeville J., Marecaux N., Fruchart J.-C., Amouyel P. Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J. Nutr. 1998, 128:1450-1457.
25. Dodmane P.R., Arnold L.L., Kakiuchi-Kiyota S., Qiu F., Liu X., Rernnard S.I., Cohen S.M. Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. Toxicology 2013, 312:18-29.
26. Ferreccio C., Yuan Y., Calle J., Benítez H., Parra R.L., Acevedo J., Smith A.H., Liaw H., Steinmaus C. Arsenic, tobacco smoke, and occupation associations of multiple agents with lung and bladder cancer. Epidemiology 2013, 24:898-905.
27. Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306(7):737-745.
28. Gabriel H.E., Crott J.W., Ghandour H., Dallal G.E., Choi S.-W., Keyes M.K., Jang H., Liu Z., Nadeau M., Johnston A., Mager D., Mason J.B. Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults. Am. J. Clin. Nutr. 2006, 83:835-841.
29. Garland M., Morris J.S., Rosner B.A., Stampfer M.J., Spate V.L., Baskett C.J., Willett W.C., Hunter D.J. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol. Biomark. Prev. 1993, 2:493-497.
30. Gamble M.V., Liu X., Slakovich V., Pilsner J.R., Ilievski V., Factor-Litvak P., Levy D., Alam S., Islam M., Parvez F., Ahsan H., Graziano J.H. Folic acid supplementation lowers blood arsenic. Am. J. Clin. Nutr. 2007, 86:1202-1209.
31. Garciafigueroa D.Y., Klei L.R., Ambrosio F., Barchowsky A. Arsenic-stimulated lipolysis and adipose remodeling is mediated by G-protein-coupled receptors. Toxicol. Sci. 2013, 134(2):335-355.
32. Gentry P.R., McDonald T.B., Sullivan D.E., Shipp A.M., Yager J.W., Clewell H.J. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ. Mol. Mutagen. 2010, 51:1-14.
33. Gibb H., Haver C., Gaylor D., Ramasamy S., Lee J.S., Lobdell D., Wade T., Chen C., White P., Sames R. Utility of recent studies to assess the National Research Council 2001 estimates of cancer risk from ingested arsenic. Environ. Health Perspect. 2011, 119:284-290.
34. Heck J.E., Andrew A.S., Onega T., Rigas J.R., Jackson B.P., Karagas M.R., Duell E.J. Lung cancer in a U.S. population with low to moderate arsenic exposure. Environ. Health Perspect. 2009, 117:1718-1723.
35. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011, Available from: www.cochrane-handbook.org. J.P.T. Higgins, S. Green (Eds.).
36. Jurek A.M., Greenland S., Maldonado G., Church T. Proper interpretation of non-differential misclassification effects: expectations vs observations. Int. J. Epidemiol. 2005, 34:680-687.
37. Jurek A.M., Greenland S., Maldonado G. How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null?. Int. J. Epidemiol. 2008, 37(2):382-385.
38. Karagas M.R., Tosteson T.D., Blum J., Klaue B., Weiss J.E., Stannard V., Spate V., Morris J.S. Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations. Am. J. Epidemiol. 2000, 152(1):84-90.
39. Karagas M.R., Stukel T.A., Tosteson T.D. Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int. J. Hyg. Environ. Health 2002, 205:85-94.
40. Karagas M.R., Tosteson T.D., Morris J.S., Demidenko E., Mott L.A., Heaney J., Schned A. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 2004, 15(5):465-472.
41. Karagas M.R., Andrew A.S., Nelson H.H., Li Z., Punshon T., Schned A., Marsit C.J., Morris J.S., Moore J.H., Tyler A.L., Gilbert-Diamond D., Guerinot M.-L., Kelsey K.T. SLC39A2 and FSIP1 polymorphisms as potential modifiers of arsenic-related bladder cancer. Hum. Genet. 2011, 131(3):453-461.
42. Kitchin K.T., Conolly R. Arsenic-induced carcinogenesis-oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. Chem. Res. Toxicol. 2010, 23:327-335.
43. Kurttio P., Pukkala E., Kahelin H., Auvinen A., Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ. Health Perspect. 1999, 107(9):705-710.
44. Lamm S.H., Engel A., Kruse M.B., Feinleib M., Byrd D.M., Lai S., Wilson R. Arsenic in drinking water and bladder cancer mortality in the United States: An analysis based on 133 U.S. counties and 30 years of observation. J. Occup. Environ. Med. 2004, 46(3):298-306.
45. Lamm S.H., Robbins S.A., Zhou C., Lu J., Chen R., Feinleib M. Bladder/lung cancer mortality in Blackfoot-disease (BFD)-endemic area villages with low (<150lg/L) well water arsenic levels - an exploration of the dose-response Poisson analysis. Regul. Toxicol. Pharmacol. 2013, 65:147-156.
46. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 1999, 107(5):359-365.
47. Meliker J.R., Slotnick M.J., AvRuskin G.A., Schottenfeld D., Jacquez G.M., Wilson M.L., Goovaerts P., Franzblau A., Nriagu J.O. Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case-control study in Michigan, USA. Cancer Causes Control 2010, 21(5):745-757.
48. Michaud D.S., Wright M.E., Cantor K.P., Taylor P.R., Virtamo J., Albanes D. Arsenic concentrations in prediagnostic toenails and the risk of bladder cancer in a cohort study of male smokers. Am. J. Epidemiol. 2004, 160(9):853-859.
49. Mink P.J., Alexander D.D., Barraj L.M., Kelsh M.A., Tsuji J.S. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Regul. Toxicol. Pharmacol. 2008, 52:299-310.
50. Moore L.E., Smith A.H., Eng C., Kalman D., DeVires S., Bhargava V., Chew K., Moore D., Ferreccio C., Rey O.A., Waldman F.M. Arsenic-related chromosomal alterations in bladder cancer. J. Natl. Cancer Inst. 2002, 94:1688-1696.
51. Morales K.H., Ryan L., Kuo T.L., Wu M.-M., Chen C.-J. Risk of internal cancers from arsenic in drinking water. Environ. Health Perspect. 2000, 108(7):655-661.
52. Arsenic in Drinking Water: 2001 Update 2001, National Research Council (NRC), National Research Council, Washington, DC.
53. Critical Aspects of EPA's IRIS Assessment of Inorganic Arsenic: Interim Report 2013, National Research Council (NRC), National Research Council, Washington, DC.
54. Nesnow S., Roop B.C., Lambert G., Kadiiska M., Mason R.P., Cullen W.R., Mass M.J. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 2002, 15:1627-1634.
55. Padrao P., Lunet N., Santos A.C., Barros H. Smoking, alcohol, and dietary choices: evidence from the Portuguese National Health Survey. BMC Public Health 2007, 7:138.
56. Pilsner J.R., Liu X., Ahsan H., Ilievski V., Slavkovich V., Levy K., Factor-Litvak P., Graziano J.H., Gamble M.V. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. Environ. Health Perspect. 2009, 117:254-260.
57. Pleis J.R., Lucas J.W., Ward B.W. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. National Center for Health Statistics. Vital Health Stat. 2009, 10(242).
58. Puente D., Hartge P., Greiser E., Cantor K.P., King W.D., González C.A., Cordier S., Vineis P., Lynge E., Chang-Claude J., Porru S., Tzonou A., Jöckel K.H., Serra C., Hours M., Lynch C.F., Ranft U., Wahrendorf J., Silverman D., Fernandez F., Boffetta P., Kogevinas M. A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. Cancer Causes Control 2006, 17(1):71-79.
59. Rothman K.J. Epidemiology: An Introduction 2002, Oxford University Press, New York.
60. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments 2005, John Wiley & Sons, Chichester, U.K. H.R. Rothstein, A.J. Sutton, M. Borenstein (Eds.).
61. Schoen A., Beck B., Sharma R., Dube E. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol. Appl. Pharmacol. 2004, 198(3):253-267.
62. Snow E.T., Sykora P., Durham T.R., Klein C.B. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol. Appl. Pharmacol. 2005, 207(2S):557-564.
63. Steinmaus C., Yuan Y., Bates M.N., Smith A.H. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol. 2003, 158(12):1193-1201.
64. Steinmaus C., Bates M.N., Yuan Y., Kalman D., Atallah R., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Hoang B.K., Smith A.H. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J. Occup. Environ. Med. 2006, 48(5):478-488.
65. Steinmaus C.M., Ferreccio C., Romo J.A., Yuan Y., Cortes S., Marshall G., Moore L.E., Balmes J.R., Liaw J., Golden T., Smith A.H. Drinking water arsenic in northern Chile: high cancer risks 40 years after exposure cessation. Cancer Epidemiol. Biomark. Prev. 2013, 22(4):623-630.
66. Suzuki S., Arnold L.L., Pennington K.L., Chen B., Naranmandura H., Le X.C., Cohen S.M. Dietary administration of sodium arsenite to rats: relations between dose and urinary concentrations of methylated and thio-metabolites and effects on the rat urinary bladder epithelium. Toxicol. Appl. Pharmacol. 2010, 244(2):99-105.
67. Tsai S.-M., Wang T.-N., Ko Y.-C. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch. Environ. Health 1999, 54(3):186-193.
68. Tseng W.-P. Effects and dose-response relationships of skin cancer and Blackfoot disease with arsenic. Environ. Health Perspect. 1977, 19:109-119.
69. Tseng W.-P., Chu H.M., How S.W., Fong J.M., Lin C.S., Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 1968, 40(3):453-463.
70. U.S.Environmental Protection Agency (EPA) Integrated Risk Information System: Arsenic 1998, U.S. Environmental Protection Agency, Carcinogenicity assessment last revised April 10, 1998. Available at: www.epa.gov/iris/subst/0278.htm (accessed 20.11.13).
71. U.S.Environmental Protection Agency (EPA) Advisory on EPA's assessments of carcinogenic effects of organic and inorganic arsenic: A report of the US EPA Science Advisory Board. U.S. Environmental Protection Agency, Science Advisory Board 2007.
72. U.S.Environmental Protection Agency (EPA) Probabilistic risk assessment for children who contact CCA-treated playsets and decks. Final Report. Prepared by J. Chen, N. Mottl, T. Lindheimer, N. Cook. U.S. Environmental Protection Agency, Office of Pesticide Programs, Antimicrobials Division, Washington, DC. 2008.
73. Toxicological review of inorganic arsenic in support of summary information on the Integrated Risk Information System (IRIS). Notice of public comment period. Fed. Reg. 2010, 75:7477-7479. U.S. Environmental Protection Agency (EPA).
74. Wu M.-M., Kuo T.-L., Hwang Y.-H., Chen C.-J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol. 1989, 130(6):1123-1132.
75. Yager J.W., Gentry P.R., Thomas R.S., Pluta L., Efremenko A., Black M., Arnold L.L., McKim J.M., Wilga P., Gill G., Choe K.-Y., Clewell H.J. Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ. Mol. Mutagen. 2013, 54:82-98.
76. Yang L., Wang W., Hou S., Peterson P.J., Williams W.P. Effects of selenium supplementation on arsenism: an intervention trial in Inner Mongolia. Environ. Geochem. Health 2002, 24:359-374.